OKYO NASDAQ
OKYO Pharma Limited
1W: -1.2%
1M: +0.6%
3M: -9.6%
YTD: -28.2%
1Y: +8.1%
3Y: +5.3%
$1.62
+0.02 (+1.25%)
Weekly Expected Move ±7.0%
$1
$1
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$61.4M
52W Range1.44-3.349
Volume36,776
Avg Volume122,142
Beta-0.05
Dividend—
Analyst Ratings
Company Info
CEORobert J. Dempsey
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2022-05-17
Websiteokyopharma.com
55 Park Lane
London W1K 1NA
GB
London W1K 1NA
GB
44 20 7495 2379
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest News
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| JACOB GARY S | 0 | — | 2026-03-18 | |
| JACOB GARY S | 21,154 | $2.13 | 2026-03-18 | |
| JACOB GARY S | 102,564 | $1.60 | 2026-03-18 | |
| JACOB GARY S | 50,000 | $1.50 | 2026-03-18 | |
| JACOB GARY S | 89,356 | $2.75 | 2026-03-18 |